1029009-61-7 Usage
Derivative of isoquinoline
Heterocyclic compound with a nitrogen-containing ring structure
Isoquinoline is the core structure of this compound, which is a type of heterocyclic compound that contains a ring with nitrogen atoms.
Substituents
3-(3-Methoxyphenyl) and N1-[(4-Methoxyphenyl)Methyl]-N7,N7-diMethylgroups
These groups are attached to the isoquinoline core, giving the compound its unique properties and structure.
Potential applications
Pharmaceuticals or other industries
Due to its unique molecular structure and properties, this compound may have potential uses in the pharmaceutical industry or other sectors. However, further research and testing are needed to fully understand its potential applications.
Need for further research and testing
To fully understand its potential uses
As with any new chemical compound, additional research and testing are necessary to determine its safety, efficacy, and potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1029009-61-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,9,0,0 and 9 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1029009-61:
(9*1)+(8*0)+(7*2)+(6*9)+(5*0)+(4*0)+(3*9)+(2*6)+(1*1)=117
117 % 10 = 7
So 1029009-61-7 is a valid CAS Registry Number.
1029009-61-7Relevant articles and documents
Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents
Yang, Su Hui,Van, Hue Thi My,Le, Thanh Nguyen,Khadka, Daulat Bikram,Cho, Suk Hee,Lee, Kyung-Tae,Chung, Hwa-Jin,Lee, Sang Kook,Ahn, Chang-Ho,Lee, Young Bok,Cho, Won-Jea
scheme or table, p. 5277 - 5281 (2010/10/21)
In the search for potent water-soluble 3-arylisoquinolines, several 3-arylisoquinolinamines were designed and synthesized. Various substituted 3-arylisoquinolinamines exhibited strong cytotoxic activity against eight different human cancer cell lines. In
